TUSC2 gene therapy in KRASG12C mutant NSCLC overcomes acquired resistance to sotorasib

被引：0
|
作者：
Meraz, I. [1 ]
Majidi, M. [1 ]
Gao, L. [1 ]
Ren, C. [1 ]
Wu, S. [1 ]
Song, R. [1 ]
Meng, F. [1 ]
Xu, Y. [1 ]
Wang, Q. [2 ]
Xi, Y. [2 ]
Wang, J. [2 ]
Jung, S. Y. [3 ]
Shpall, E. [4 ]
Roth, J. A. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Thorac & Cardiovasc Surg, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Bioinformat & Computat Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Biochem, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat, Houston, TX 77030 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB372
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [41] Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R
    Qi, Wei-liang
    Li, Hui-yu
    Wang, Yi
    Xu, Lan
    Deng, Jie-ting
    Zhang, Xi
    Wang, Yu-xiang
    Meng, Ling-hua
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (05) : 1083 - 1094
  • [42] Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R
    Wei-liang Qi
    Hui-yu Li
    Yi Wang
    Lan Xu
    Jie-ting Deng
    Xi Zhang
    Yu-xiang Wang
    Ling-hua Meng
    Acta Pharmacologica Sinica, 2023, 44 : 1083 - 1094
  • [43] KRASG12c-Mutant NSCLC Under Targeted Therapy in China: Lessons from Eight Cases
    Li, Y.
    Dai, M.
    Zhang, R.
    Nie, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S649 - S649
  • [44] Combination RASG12C(ON) and RASMULTI(ON) inhibition overcomes resistance and prolongs durability in preclinical models of mutant KRASG12C-driven cancers
    Wei, Xing
    Holderfield, Matthew
    Yang, Yu Chi
    Seamon, Kyle
    Dinglasan, Jay
    Montazar, Nilufar
    Lee, Bianca
    Cai, Shurui
    Lai, Lick
    Aronchik, Ida
    Chang, Stephanie
    Wang, Zhican
    Wildes, Pete
    Smith, Jacqueline A.
    Jiang, Jingjing
    Singh, Mallika
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
    Thatikonda, Venu
    Lyu, Hengyu
    Jurado, Sabine
    Kostyrko, Kaja
    Bristow, Christopher A.
    Albrecht, Christoph
    Alpar, Donat
    Arnhof, Heribert
    Bergner, Oliver
    Bosch, Karin
    Feng, Ningping
    Gao, Sisi
    Gerlach, Daniel
    Gmachl, Michael
    Hinkel, Melanie
    Lieb, Simone
    Jeschko, Astrid
    Machado, Annette A.
    Madensky, Thomas
    Marszalek, Ethan D.
    Mahendra, Mikhila
    Melo-Zainzinger, Gabriella
    Molkentine, Jessica M.
    Jaeger, Philipp A.
    Peng, David H.
    Schenk, Robyn L.
    Sorokin, Alexey
    Strauss, Sandra
    Trapani, Francesca
    Kopetz, Scott
    Vellano, Christopher P.
    Petronczki, Mark
    Kraut, Norbert
    Heffernan, Timothy P.
    Marszalek, Joseph R.
    Pearson, Mark
    Waizenegger, Irene C.
    Hofmann, Marco H.
    NATURE CANCER, 2024, 5 (09) : 1352 - 1370
  • [46] High EGFR Expression Confers Acquired Resistance to Adagrasib - In Vitro Study Using KRASg12C Mutated Lung Cancer Cells
    Hamada, A.
    Suda, K.
    Obata, K.
    Sato, H.
    Oiki, H.
    Fukuda, S.
    Ohara, S.
    Ito, M.
    Soh, J.
    Tsutani, Y.
    Mitsudomi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S315 - S315
  • [47] Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN)
    Scott, S. C.
    Hu, C.
    Smith, K.
    Anagnostou, V.
    Lee, J.
    Spicer, J.
    Illei, P.
    Prophet, E.
    Rosner, S.
    Ettinger, D.
    Feliciano, J.
    Hann, C.
    Lam, V.
    Levy, B.
    Murray, J.
    Brahmer, J.
    Forde, P.
    Marrone, K.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S235 - S235
  • [48] Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 Studies
    Nagase, Mario
    Houk, Brett
    Vuu, Irene
    Cardona, Panli
    Dutta, Sandeep
    Lin, Chih-Wei
    AAPS JOURNAL, 2025, 27 (01):
  • [49] Targeting transcriptional elongation kinases prevents adaptation to KRASG12C inhibitors in both MAPK-dependent and -independent models of acquired resistance
    Stern, Yaakov E.
    Ghosh, Pompom
    Solanki, Hitendra S.
    Imbody, Denis
    Bridenstine, Liznair
    Walker-Mimms, Hannah L.
    Mosior, John W.
    Monastyrskyi, Andrii
    Duckett, Derek R.
    Haura, Eric B.
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [50] Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
    Fakih, Marwan G.
    Kopetz, Scott
    Kuboki, Yasutoshi
    Kim, Tae Won
    Munster, Pamela N.
    Krauss, John C.
    Falchook, Gerald S.
    Han, Sae-Won
    Heinemann, Volker
    Muro, Kei
    Strickler, John H.
    Hong, David S.
    Denlinger, Crystal S.
    Girotto, Gustavo
    Lee, Myung-Ah
    Henary, Haby
    Tran, Qui
    Park, Joseph K.
    Ngarmchamnanrith, Gataree
    Prenen, Hans
    Price, Timothy J.
    LANCET ONCOLOGY, 2022, 23 (01): : 115 - 124
12345